InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,722.26
(
-0.19%
)
US TECH 100
19,518.00
(
0.53%
)
Dow Jones
41,914.75
(
-0.70%
)
Brent Oil
71.59
(
-2.19%
)
Bitcoin
63,668.65
(
0.85%
)
Post# of 1011
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

cbdstockswatcher

Send PM Follow Ignore
Followers 0
Posts 13
Boards Moderated 0
Alias Born 01/02/2019

cbdstockswatcher

Re: None

Monday, 01/28/2019 8:06:09 PM

Monday, January 28, 2019 8:06:09 PM

Post# of 1011
"Today we’re pleased to report that three landmark milestones have now been met by MGC Pharma.

1. Our CTN (Clinical Trial Notification) for CogniCann™ into Alzheimer’s and dementia at the University of Notre Dame is now available in the Clinical Trials Repository.

2. We are one of the first EU facilities to be granted a full API extraction permit to develop our own THC, CBD and other Phytocannabinoids for use in CannEpil™, CogniCann™ and future phytomedicines.

3. We have received SME certification from the European Medicines Agency (EMA) for the scientific advice, drug evaluation and registration of CannEpil™, CogniCann™ and additional Phytomedicines that the Company is developing.

These are landmark milestones for the MGC Pharma company and are a testament to the continuous hard work we’re putting in to become a global market leader in phytocannabinoids."

Read the full announcement here: http://snip.ly/bx35d9
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up